New Results on Treatment of Gynaecological Cancers - European Cancer Congress (ESMO) 2023

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

New Results for Treatment of Colorectal Cancer - European Cancer Congress (ESMO) 2023Подробнее

Highlights in gynecological cancers at ESMO 2023Подробнее

New Results for Treatment of Rectal Cancer - European Cancer Congress (ESMO) 2023Подробнее

New Results on Treatment of Metastatic Breast Cancer - European Cancer Congress (ESMO) 2023Подробнее

New Results for Treatment of Metastatic Stomach Cancer - European Cancer Congress (ESMO) 2023Подробнее

New Results for Treatment of Colon Cancer - European Cancer Congress (ESMO) 2023Подробнее

ESMO Gynaecological Cancers Congress: key developments in ovarian cancerПодробнее

Updates in gynecological cancers at ESMO 2023Подробнее

New Results on Treatment of Early Breast Cancer - European Cancer Congress (ESMO) 2023Подробнее

ESMO 2023 highlights in the treatment of ovarian cancerПодробнее

#ESMO23: Learn about the latest practice challenges & controversies in oncology today, Karin JordanПодробнее

ESMO Gynaecological Cancers Congress 2024: Share your research at #ESMOGynae24Подробнее

Updates in melanoma at ESMO 2023Подробнее

Advances in colorectal cancer therapies at ESMO 2023Подробнее

ESMO Sarcoma and Rare Cancers 2024: Why you should submit your abstract with Claudia ValverdeПодробнее

Ovarian cancer at ESMO 2024: PRIMA and ATHENAПодробнее

New Results for Treatment of Non-Metastatic Stomach Cancer - European Cancer Congress (ESMO) 2023Подробнее

Highlights in sarcoma at ESMO 2023Подробнее

Novel findings in the treatment and disease biology of head and neck cancers at ESMO 2023Подробнее